FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a recombinant nucleic acid molecule for increasing the efficiency of producing a transgene expressed in a mammalian cell. Recombinant according to the present invention is designed so that it includes 5'-3'-transposon-specific end repeat of ITR, a nucleic acid coding a TEP transporter protein or a TEP RNA, and is also supplemented with an epigenetic regulatory element. In addition, a recombinant expression vector, a host cell, a method for expressing the encoded TEP, a cell transfection method and a cell transfection kit are described.
EFFECT: in comparison with known analogues, the invention demonstrates advantages in relation to expression value and quality, including high stability of transgene expression and, if necessary, transportation of the expressed product to the outside of the cell.
64 cl, 4 tbl, 25 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| MUTANT NITRILE HYDRATASE, NUCLEIC ACID WHICH ENCODES SAID MUTANT NITRILE HYDRATASE, EXPRESSION VECTOR AND TRANSFORMANT CONTAINING SAID NUCLEIC ACID, METHOD OF PRODUCING SAID MUTANT NITRILE HYDRATASE AND METHOD OF PRODUCING AMIDE COMPOUND | 2017 |
|
RU2736086C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| RECOMBINANT PROTEINS WITH CCN DOMAINS AND FUSION PROTEINS | 2020 |
|
RU2825102C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
